Skip to content
- World’s first self-stabilising exoskeleton, Atlante X, developed by Paris-based healthtech firm Wandercraft, has begun a rehabilitation trial in Germany.
- The trial, titled EarlyExo, will evaluate the device’s effectiveness in helping stroke patients recover walking ability, trunk stability, balance, weight transfer, and limb function. The study will take place at two renowned neurorehabilitation clinics where 66 patients have been recruited.
- The U.S. FDA had previously cleared Atlante X for usage in stroke rehabilitation. The company has garnered around $67mn in investments for its innovative medical device.
- Following a strong commercial presence within Europe, including France and Spain, Wandercraft aims to penetrate the US market next.